Join the Alunbrig group to help and get support from people like you.
Alunbrig News
FDA Approves Takeda’s Alunbrig (brigatinib) as a First-Line Treatment Option for Patients with ALK+ Metastatic Non-Small Cell Lung Cancer (NSCLC)
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE) May 22, 2020 --Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) approved...
Takeda Announces FDA Accelerated Approval of Alunbrig (brigatinib)
Cambridge, Mass. and Osaka, Japan – April 28, 2017 – Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that Alunbrig (brigatinib) has received Accelerated Approval from the U.S. Food a...